These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 15810178)
1. Protection of children and risks with medical devices. Maloney DM Hum Res Rep; 2004 Dec; 19(12):3. PubMed ID: 15810178 [No Abstract] [Full Text] [Related]
2. IOM advises FDA on ethics in postmarket safety trials. Kuehn BM JAMA; 2010 Aug; 304(6):627. PubMed ID: 20699450 [No Abstract] [Full Text] [Related]
3. How should adverse events be reported in US clinical trials?: ethical considerations. Shamoo AE; Katzel LI Clin Pharmacol Ther; 2008 Aug; 84(2):275-8. PubMed ID: 18305454 [TBL] [Abstract][Full Text] [Related]
4. Congress responds to the IOM drug safety report--in full. Psaty BM; Korn D JAMA; 2007 Nov; 298(18):2185-7. PubMed ID: 18000202 [No Abstract] [Full Text] [Related]
5. Accreditation of human research participant protection programs. Maloney DM Hum Res Rep; 2001 Jun; 16(6):1-2. PubMed ID: 11785525 [No Abstract] [Full Text] [Related]
6. The report by the Institute of Medicine and postmarketing surveillance. Klein DF Arch Gen Psychiatry; 1999 Apr; 56(4):353-4. PubMed ID: 10197831 [No Abstract] [Full Text] [Related]
7. Encouraging research and development of pediatric medical devices through legislative and regulatory action: the Pediatric Medical Device Safety and Improvement Act of 2007 in context. Bleicher EW Food Drug Law J; 2009; 64(3):531-64. PubMed ID: 19999642 [TBL] [Abstract][Full Text] [Related]
8. FDA gets feedback on informed consent waiver. Marwick C JAMA; 1996 Feb; 275(5):347. PubMed ID: 8568998 [No Abstract] [Full Text] [Related]
9. IOM outlines framework for postmarket safety. Reinke T Manag Care; 2012 Aug; 21(8):10-1. PubMed ID: 22957462 [No Abstract] [Full Text] [Related]
10. Reply to "Can the Institute of Medicine review the FDA?". Fineberg HV Nat Med; 2005 Jun; 11(6):589. PubMed ID: 15937463 [No Abstract] [Full Text] [Related]
11. Institutional review boards and medical devices. Less JR; Alpert S; Nightingale SL JAMA; 1994 Sep; 272(12):968-9. PubMed ID: 8084066 [No Abstract] [Full Text] [Related]
12. The report of the Institute of Medicine on drug safety. Somberg J Am J Ther; 2007; 14(1):1-2. PubMed ID: 17303967 [No Abstract] [Full Text] [Related]
13. Panel backs pregnant women in trials. Anderson C Science; 1994 Mar; 263(5151):1216. PubMed ID: 8122099 [No Abstract] [Full Text] [Related]
14. Major changes recommended for protecting human research subjects. Maloney DM Hum Res Rep; 2002 Nov; 17(11):1-2. PubMed ID: 12708411 [No Abstract] [Full Text] [Related]
16. The FDA in 2006: reasons for optimism. Chabner BA; Roberts TG Oncologist; 2007 Mar; 12(3):247-9. PubMed ID: 17405888 [No Abstract] [Full Text] [Related]
17. Children need more protection in clinical trials, says IOM. Panel concludes that current regulations are misapplied, but stops short of calling for strict enforcement. Ault A Lancet; 2004 Apr; 363(9415):1119. PubMed ID: 15068011 [No Abstract] [Full Text] [Related]
18. FDA should tighten post-marketing surveillance of prescription drugs, says Institute of Medicine. Roehr B BMJ; 2012 May; 344():e3104. PubMed ID: 22549070 [No Abstract] [Full Text] [Related]
19. Institute of Medicine, Congress seek solutions to FDA's safety woes through reform, funding. Finkelstein JB J Natl Cancer Inst; 2007 Jan; 99(2):104-7. PubMed ID: 17227990 [No Abstract] [Full Text] [Related]
20. Ethical conduct of clinical research involving children. Bull Med Ethics; 2004 Sep; (201):8-11. PubMed ID: 15685752 [No Abstract] [Full Text] [Related] [Next] [New Search]